SSTR2 and neuroendocrine neoplasm: Examples include a phase I dose escalation study of [212Pb]Pb-DOTAM-GRPR1 in metastatic tumors positive for the gastrin releasing peptide receptor (NCT05283330), a phase I/IIa clinical trial using [212Pb]Pb-VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors (NCT05636618), and a first-in-human study of [212Pb]VMT01 in patients with unresectable metastatic melanoma expressing the melanocortin sub-type 1 receptor (NCT05655312).